EXICURE Aktie

 

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN ALTURA ENERGY CORP. Y020 CA02210E1016 BECKETTS INC. O.N. T270 CA07568L1022 CAMINO MINERALS XC0 CA1380503070 GLENSTAR MINERALS INC. VO20 CA37888C1023 GOLD FINDERS RESOURCES 6NR CA38059A1075 NOBLE PLAINS URANIUM INE0 CA65510H1082 PARADIGM GOLD CORP. C5N CA69902F1009 SOKOMAN MIN.CORP. NEW 3PJ CA83410N1096 AMS-OSRAM UNSPON.ADR NEW DQW0 US03217C2052 DBV TECH.SP.ADR 5 EO-10 DBV1 US23306J3095 EMBRACER GROUP UNSP.ADR/1 TH93 US29082P2039 EXICURE INC. DL-,0001 2H0 US30205M3097 FITLIFE BRANDS INC. O.N. QO...

U.S. stock futures up, focus on PRGS, XCUR, QMCO earnings. VERO jumps 43.6% after stake increase, IGC reports positive results. Check out Cramer's oil pick. Photo: Shutterstock. read more...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. (“GPCR USA”), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses. General and Administrative (G&A) Expense: General and administrative expenses were $2.2 million for the quarter ended March...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2025 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q by May 20, 2025 for the quarterly period ended March 31, 2025 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). Under Nasdaq's listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 10-Q due date, or until November 17, 2025, to regain compliance. The Company is working diligently to complete its Form 10-Q and intends to file the Form 10-Q as soon as...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. 2024 Financial Results Cash Position: Cash and cash equivalents were $12.5 million as of December 31, 2024, as compared to $0.8 million as of December 31, 2023. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be needed to fund our ongoing operations and exploratio...

SANTA CLARA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.55 A.M. ET).In the Green Aveanna Healthcare Holdings Inc. (AVAH) is up over......

SANTA CLARA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.55 A.M. ET).In the Green Aveanna Healthcare Holdings Inc. (AVAH) is up over......

CHICAGO--(BUSINESS WIRE)--Please replace the release dated January 22, 2025 with the following corrected version due to multiple revisions. The updated release reads: EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC. Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation (“GPCR”), pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation (“GPCR USA”). The transactions completed under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately prior to closing under the Share Purchase Agreement, a wholly owned subsidiary of GPCR. In connection with the closing of the Share Purchase Agreement, the Company and GPCR entered into a License and Collaboration Agreement (“L&C Ag...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation (“GPCR”), pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation (“GPCR USA”). The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately prior to closing under the Share Purchase Agreement, a wholly owned subsidiary of GPCR. In connection with the closing of the Share Purchase Agreement, the Company and GPCR entered into a License and Collaboration Agreement (“L&C Agreement”) to further develop and commercialize GPCR's technologies related to certain intellectual property and patents. The L&C Agreement requires the Company to make milestone payments to GPCR upon the ac...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics' ongoing drug development pipelines. Through this acquisition, Exicure plans to secure key technical personnel by purchasing all shares of GPCR USA held by GPCR Therapeutics. Following this, Exicure intends to receive technology transfer for GPCR Therapeutics' CXCR4 inhibitor, which is currently in Phase 2 clinical trials with the FDA, along with its related patents and intellectual property (IP). By acquiring excellent research personnel and clinical pipelines, Exicure aims to advance as a clinical-stage biotech company. GPCR Therapeutics plans to successfully finalize ongoing clinical trials involving stem cell mobilizers (SCM)...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.10 A.M. ET).In the Green Heron Therapeutics, Inc. (HRTX) is up over 66% at $1.......

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL EXICURE INC. DL-,0001 2H0 US30205M3097 BAW/UFN...

Instrument ID [20756359] (2H0 - US30205M3097) suspended...

Das Instrument 2H0 US30205M3097 EXICURE INC. DL-,0001 EQUITY hat seinen ersten Handelstag am 28.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument 2H0 US30205M3097 EXICURE INC. DL-,0001 EQUITY has its first trading date on 28.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US34962G1094 Forte Biosciences Inc. 27.08.2024 US34962G2084 Forte Biosciences Inc. 28.08.2024 Tausch 25:1 US30205M2008 Exicure Inc. 27.08.2024 US30205M3097 Exicure Inc. 28.08.2024 Tausch 5:1 KYG7785S1075 Sanai Health Industry Group Co. Ltd. 27.08.2024 KYG7785S1158 Sanai Health Industry Group Co. Ltd. 28.08.2024 Tausch 25:1...